Protocol amendments and excessive monitoring inflate oncology trial costs and extend timelines. This session shows how Gabrail Cancer Center evaluates operational realism before first patient in to protect sponsor capital and timeline integrity.
Who Should Attend
• Sponsor Trial Design Teams
• Clinical Operations Leaders
• Regulatory Affairs Executives
• Budget and Contracting Leads
• CRO Oversight Managers
Agenda
Amendment Culture as Financial Risk: Frequent changes signal early design misalignment and drive cost escalation.
Endpoint Inflation and Operational Drag: Too many endpoints reduce throughput and increase protocol deviations.
Monitoring Burden and Site Fatigue: Over-monitoring slows enrollment and destabilizes execution quality.
KPIs That Predict Budget Drift: Deviation rates and visit intensity reveal exposure early.
Q & A – Polls – Handouts We will capture your feedback through polls, answer sponsor-level questions, and provide a downloadable Protocol Risk checklist.
Duration
1 hour
Price
Free
Language
English
OPEN TO
Everyone
Dial-in Number
Please register for this Webinar to view the dial-in info.
Dr. Gabrail is a graduate of Mosul Medical School in Iraq. He completed his graduate Internal Medicine education at The University of Edinburgh, Scotland and Hematology/Oncology in Glasgow, Scotland.
Carrie Smith, R.N. began her oncology career in 1998 as an oncology nurse at Gabrail Cancer Center. The following year she realized that access to clinical trials should be the preferred standard of care for all cancer patients. Carrie was...
Gabrail Cancer & Research Center: Founded by Dr. Nashat Gabrail in 1990, the Gabrail Cancer Center was opened in Stark County in Ohio. Due to the increasing amount of patients traveling long distances for treatment, a satellite office was opened...
About BioAlliance Strategies
Founded in 2011, BioAlliance Strategies solves a persistent problem in life sciences growth. There was a definite need to build a revenue infrastructure system for smaller companies where high-dollar sales teams...